scholarly journals Current Status of Functional Studies on Circular RNAs in Bladder Cancer and their Potential Role as Diagnostic and Prognostic Biomarkers: A Review

2019 ◽  
Vol 25 ◽  
pp. 3425-3434 ◽  
Author(s):  
Liang Cong ◽  
Qiwei Yang ◽  
Chunmei Hu ◽  
Qiong Yu ◽  
Shuhong Hao ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Potential Role ◽  
Prognostic Biomarkers ◽  
Current Status ◽  
Circular Rnas ◽  
Functional Studies

scholarly journals Current status and potential role of circular RNAs in neurological disorders

2019 ◽  
Vol 150 (3) ◽  
pp. 237-248 ◽  
Author(s):  
Shanshan Lu ◽  
Xue Yang ◽  
Chudong Wang ◽  
Siqi Chen ◽  
Shuang Lu ◽  
...  
Keyword(s):  
Neurological Disorders ◽  
Potential Role ◽  
Current Status ◽  
Circular Rnas

Nonmuscle-Invasive Bladder Cancer: What's Changing and What has Changed

2017 ◽  
Vol 84 (1) ◽  
pp. 1-8 ◽  
Author(s):  
Ramanitharan Manikandan ◽  
Oscar Rodriguez ◽  
Rubén Parada ◽  
Joan Palou Redorta
Keyword(s):  
Bladder Cancer ◽  
Best Practice ◽  
Disease Recurrence ◽  
Invasive Bladder Cancer ◽  
Current Status ◽  
Optimal Care ◽  
Medline Search ◽  
Select Group ◽  
The Future ◽  
Nonmuscle Invasive Bladder Cancer

Purpose Nonmuscle-invasive bladder cancer (NMIBC) is a challenging disease to manage primarily due to its varied clinical course. The management of NMIBC has witnessed a widespread change with respect to its diagnosis and treatment. Although transurethral resection (TUR) and adjuvant bacillus Calmette–Guerin (BCG) stills remain the cornerstone, newer protocols has come into vogue to achieve optimal care. On the basis of a literature review, we aimed to establish ‘what changes has already occurred and what is expected in the future’ in NMIBC. Methods A Medline search was performed to identify the published literature with respect to diagnosis, treatment and future perspectives on NMIBC. Particular emphasis was directed to determinants such as the quality of TUR and the newer modifications, Re-TUR, current status of newer macroscopic and microscopic imaging, role of urinary biomarkers, clinical, histologic and molecular predictors of high-risk disease, administration of intravesical agents, salvage therapy in BCG recurrence and the current best practice guidelines were analyzed. Results and Conclusions Optimal TUR, restaging in select group, incorporation of newer endoscopic imaging and judicious administration of intravesical chemo-immunotherapeutic agents can contribute to better patient care. Although there is a plethora of urinary markers, there is insufficient evidence for their use in isolation. The future probably lies in identification of genetic markers to determine disease recurrence, nonresponders to standard treatment and early institution of alternative/targeted therapy.

935 Potential role of an IRE1α/XBP1 inhibitor in preventing therapeutic failure of intravesical BCG in bladder cancer

2016 ◽  
Vol 15 (3) ◽  
pp. e935
Author(s):  
P. Lewicki ◽  
H. Liu ◽  
D. Golombos ◽  
P. O'Malley ◽  
J. Cubillos-Ruiz ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Potential Role ◽  
Therapeutic Failure ◽  
Intravesical Bcg

scholarly journals Podocalyxin-like and RNA-binding motif protein 3 are prognostic biomarkers in urothelial bladder cancer: a validatory study

2017 ◽  
Vol 5 (1) ◽  
Author(s):  
Karolina Boman ◽  
Gustav Andersson ◽  
Christoffer Wennersten ◽  
Björn Nodin ◽  
Göran Ahlgren ◽  
...  
Keyword(s):  
Bladder Cancer ◽  
Rna Binding ◽  
Prognostic Biomarkers ◽  
Binding Motif ◽  
Urothelial Bladder Cancer ◽  
Urothelial Bladder
Sign in / Sign up

Export Citation Format

Share Document